These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32501837)

  • 1. Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom.
    van Halsema CL; Okhai H; Hill T; Sabin CA;
    AIDS; 2020 Oct; 34(12):1813-1821. PubMed ID: 32501837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?
    Grant AD; Bansi L; Ainsworth J; Anderson J; Delpech V; Easterbrook P; Fisher M; Gazzard B; Gilson R; Gompels M; Hill T; Johnson M; Leen C; Orkin C; Phillips AN; Porter K; Post F; Walsh J; Sabin CA;
    AIDS; 2009 Nov; 23(18):2507-15. PubMed ID: 19770622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland.
    Gupta RK; Rice B; Brown AE; Thomas HL; Zenner D; Anderson L; Pedrazzoli D; Pozniak A; Abubakar I; Delpech V; Lipman M
    Lancet HIV; 2015 Jun; 2(6):e243-51. PubMed ID: 26423197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
    del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
    Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in HIV clinical outcomes amongst heterosexuals in the United Kingdom by ethnicity.
    Dhairyawan R; Okhai H; Hill T; Sabin CA;
    AIDS; 2021 Sep; 35(11):1813-1821. PubMed ID: 33973878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of tuberculosis and the need of prophylactic treatment in persons living with HIV in Stockholm during the era of anti-retroviral therapy 1996-2013.
    Norrby M; Wannheden C; Ekström AM; Berggren I; Lindquist L
    Infect Dis (Lond); 2018; 50(11-12):807-816. PubMed ID: 30362392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of tuberculosis in the first year of antiretroviral therapy in the Botswana National antiretroviral therapy programme between 2011 and 2015.
    Mupfumi L; Moyo S; Shin SS; Wang Q; Zetola N; Molebatsi K; Nnawa J; Kgwaadira BT; Bewlay L; Chebani T; Iketleng T; Mogashoa T; Makhema J; Musonda RM; Essex M; Kasvosve I; Gaseitsiwe S
    AIDS; 2019 Dec; 33(15):2415-2422. PubMed ID: 31764106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
    Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
    BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies.
    Fenner L; Atkinson A; Boulle A; Fox MP; Prozesky H; Zürcher K; Ballif M; Furrer H; Zwahlen M; Davies MA; Egger M;
    J Int AIDS Soc; 2017 Jun; 20(1):21327. PubMed ID: 28691438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV.
    Winter JR; Stagg HR; Smith CJ; Brown AE; Lalor MK; Lipman M; Pozniak A; Skingsley A; Kirwan P; Yin Z; Thomas HL; Delpech V; Abubakar I
    AIDS; 2017 Nov; 31(17):2403-2413. PubMed ID: 28857827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy.
    Liu E; Makubi A; Drain P; Spiegelman D; Sando D; Li N; Chalamilla G; Sudfeld CR; Hertzmark E; Fawzi WW
    AIDS; 2015 Jul; 29(11):1391-9. PubMed ID: 26091295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake and outcome of combination antiretroviral therapy in men who have sex with men according to ethnic group: the UK CHIC Study.
    United Kingdom Collaborative HIV Cohort Study Group
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):523-9. PubMed ID: 22205437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.
    Soeters HM; Sawry S; Moultrie H; Rie AV
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):136-44. PubMed ID: 25072611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan.
    Lee YC; Hung CC; Tsai MS; Zhang JY; Wu PY; Yang SP; Luo YZ; Chang HY; Liu WC; Sun HY; Chang SC
    J Microbiol Immunol Infect; 2018 Feb; 51(1):38-44. PubMed ID: 27329131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi.
    Tweya H; Feldacker C; Mpunga J; Kanyerere H; Heller T; Ganesh P; Nkosi D; Kalulu M; Sinkala G; Satumba T; Phiri S
    J Int AIDS Soc; 2019 Apr; 22(4):e25240. PubMed ID: 31038836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?
    Pettit AC; Jenkins CA; Stinnette SE; Rebeiro PF; Blackwell RB; Raffanti SP; Shepherd BE; Sterling TR
    J Acquir Immune Defic Syndr; 2011 Aug; 57(4):305-10. PubMed ID: 21423024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort.
    Mussini C; Galli L; Lepri AC; De Luca A; Antinori A; Libertone R; Angarano G; Bonfanti P; Castagna A; DʼArminio Monforte A;
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):339-45. PubMed ID: 23591636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.
    Gupta A; Wood R; Kaplan R; Bekker LG; Lawn SD
    PLoS One; 2012; 7(3):e34156. PubMed ID: 22479548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.
    Van Rie A; Westreich D; Sanne I
    J Acquir Immune Defic Syndr; 2011 Apr; 56(4):349-55. PubMed ID: 20926954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.